Invitrogen, Avista Capital Holdings L.P. deal

IVGN sold its BioReliance Corp. contract research business unit to private equity firm Avista for $210 million. IVGN acquired BioReliance, which provides biological safety testing, toxicology, viral manufacturing and laboratory animal diagnostic services, for $500 million in 2004. UBS advised IVGN on the deal, which is expected to close in 2Q07. IVGN expects the divestiture to be EPS neutral in 2007. ...